LIPO
Lipella Pharmaceuticals Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.06 |
| Day High | $0.06 |
| Day Low | $0.03 |
| Volume | 160,086 |
Stock Information
| Shares Outstanding | 4.62M |
| Total Debt | $264K |
| Cash Equivalents | $1.86M |
| Revenue | $390K |
| Net Income | $-5.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3K |
| EPS (TTM) | $-2.71 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.59M |
| Sales | $390K |
| Income | $-5.33M |
| Book/sh | $0.32 |
| Cash/sh | $0.40 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 2.89 |
| Current Ratio | 3.24 |
| Debt/Eq | 17.75 |
Returns & Margins
| ROA | -149.95% |
| ROE | -361.77% |
| Operating Margin | -1387.94% |
Ownership
| Insider Ownership | 6.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.00 |
| P/S | 0.01 |
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.07 |
| RSI | 50.00 |
| ATR | 0.0000 |
| Shares Float | 4.33M |
| Short Float | 1.57% |
| Short Ratio | 1.82 |
| Volatility | 1.74 |
Performance History
| Week | +20.00% |
| Month | +20.00% |
| Quarter | +200.00% |
| 6 Months | -97.74% |
| YTD | -99.65% |
| Year | -99.86% |
| 3 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-11-03 | $0.00 | 0 |
| 2026-11-02 | $0.00 | 0 |
| 2026-10-30 | $0.00 | 0 |
| 2026-10-29 | $0.00 | 0 |
| 2026-10-28 | $0.00 | 353 |
| 2026-10-27 | $0.00 | 0 |
| 2026-10-26 | $0.00 | 1,682 |
| 2026-10-23 | $0.00 | 915 |
| 2026-10-22 | $0.00 | 0 |
| 2026-10-21 | $0.00 | 0 |
| 2026-10-20 | $0.00 | 310 |
| 2026-10-19 | $0.00 | 0 |
| 2026-10-16 | $0.00 | 400 |
| 2026-10-15 | $0.00 | 0 |
| 2026-10-14 | $0.00 | 0 |
| 2026-10-13 | $0.00 | 0 |
| 2026-10-12 | $0.00 | 236 |
| 2026-10-09 | $0.00 | 300 |
| 2026-10-08 | $0.00 | 0 |
| 2026-10-07 | $0.00 | 2,894 |
| 2026-10-06 | $0.00 | 0 |
| 2026-10-05 | $0.00 | 0 |
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
đ° Latest News
No news articles available at the moment. Check back later for updates on LIPO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,613,187 | $3,038,836 | $2,547,677 | $1,456,791 |
| Cost Of Revenue | $3,613,187 | $3,038,836 | $2,547,677 | $1,456,791 |
| Total Revenue | $536,357 | $449,617 | $184,156 | $259,347 |
| Operating Revenue | $536,357 | $449,617 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $10,848 | $9,612 | $6,834 |
| Total Expenses | $5,616,899 | $5,195,570 | $2,773,869 | $2,175,175 |
| Net Non Operating Interest Income Expense | $64,278 | $126,988 | $-7,934 | $-6,730 |
| Interest Expense Non Operating | $0 | $10,848 | $9,612 | $6,834 |
| Operating Expense | $2,003,712 | $2,156,734 | $226,192 | $718,384 |
| General And Administrative Expense | $2,003,712 | $2,156,734 | $226,192 | $718,384 |
| Other Income Expense | - | - | $-45 | $57,085 |
| Other Non Operating Income Expenses | - | - | $-45 | $57,085 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Net Interest Income | $64,278 | $126,988 | $-7,934 | $-6,730 |
| Interest Income | $64,278 | $137,836 | $1,678 | $104 |
| Normalized Income | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Net Income From Continuing And Discontinued Operation | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Total Operating Income As Reported | $-5,080,542 | $-4,745,953 | $-2,589,713 | $-1,915,828 |
| Net Income Common Stockholders | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Net Income | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Net Income Including Noncontrolling Interests | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Net Income Continuous Operations | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Pretax Income | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Interest Income Non Operating | $64,278 | $137,836 | $1,678 | $104 |
| Operating Income | $-5,080,542 | $-4,745,953 | $-2,589,713 | $-1,915,828 |
| Gross Profit | $-3,076,830 | $-2,589,219 | $-2,363,521 | $-1,197,444 |
| Per Share | ||||
| Diluted EPS | $-4.79 | $-6.16 | $-5.12 | $-2.60 |
| Basic EPS | $-4.79 | $-6.16 | $-5.12 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,013,378 | $-4,606,432 | $-2,588,080 | $-1,858,639 |
| Reconciled Depreciation | $2,886 | $1,685 | $0 | - |
| EBITDA (Bullshit earnings) | $-5,013,378 | $-4,606,432 | $-2,588,080 | $-1,858,639 |
| EBIT | $-5,016,264 | $-4,608,117 | $-2,588,080 | $-1,858,639 |
| Diluted Average Shares | $1,048,185 | $750,383 | $507,578 | $717,993 |
| Basic Average Shares | $1,048,185 | $750,383 | $507,578 | $717,993 |
| Diluted NI Availto Com Stockholders | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Selling General And Administration | $2,003,712 | $2,156,734 | $226,192 | $718,384 |
| Other Gand A | $2,003,712 | $2,156,734 | $226,192 | $718,384 |
| Research And Development | - | - | $2,547,677 | $1,456,791 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,919,453 | $3,144,448 | $4,675,596 | $1,423,552 |
| Total Assets | $2,673,870 | $3,577,174 | $5,950,110 | $2,012,889 |
| Total Non Current Assets | $56,618 | $147,894 | $150,821 | $204,800 |
| Current Assets | $2,617,252 | $3,429,280 | $5,799,289 | $1,808,089 |
| Prepaid Assets | $347,676 | $103,256 | $563,891 | $93,715 |
| Receivables | $84,713 | $32,286 | $113,655 | $0 |
| Other Receivables | $84,713 | $32,286 | $113,655 | - |
| Cash Cash Equivalents And Short Term Investments | $2,184,863 | $3,293,738 | $5,121,743 | $1,714,374 |
| Cash And Cash Equivalents | $2,184,863 | $3,293,738 | $5,121,743 | $1,413,828 |
| Debt | ||||
| Total Debt | $47,605 | $136,594 | $429,520 | $282,961 |
| Long Term Debt And Capital Lease Obligation | $0 | $47,371 | $96,258 | $218,363 |
| Current Debt And Capital Lease Obligation | $47,605 | $89,223 | $333,262 | $64,598 |
| Current Debt | - | - | $275,000 | $25,000 |
| Other Current Borrowings | - | - | $275,000 | $25,000 |
| Long Term Debt | - | - | - | $50,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $754,417 | $432,726 | $1,274,514 | $589,337 |
| Total Non Current Liabilities Net Minority Interest | $0 | $47,371 | $96,258 | $248,712 |
| Current Liabilities | $754,417 | $385,355 | $1,178,256 | $340,625 |
| Payables And Accrued Expenses | $706,812 | $296,132 | $844,994 | $276,027 |
| Payables | $388,191 | $190,066 | $384,357 | $46,900 |
| Accounts Payable | $388,191 | $138,016 | $384,357 | $46,900 |
| Interest Payable | - | $0 | $3,596 | $27,445 |
| Total Tax Payable | - | $52,050 | - | - |
| Tradeand Other Payables Non Current | - | - | $0 | $30,349 |
| Other Current Liabilities | - | - | $67,832 | $50,161 |
| Equity | ||||
| Common Stock Equity | $1,919,420 | $3,144,448 | $4,675,596 | $1,423,393 |
| Preferred Stock Equity | $33 | - | - | $159 |
| Total Equity Gross Minority Interest | $1,919,453 | $3,144,448 | $4,675,596 | $1,423,552 |
| Stockholders Equity | $1,919,453 | $3,144,448 | $4,675,596 | $1,423,552 |
| Retained Earnings | $-15,340,107 | $-10,323,843 | $-5,704,878 | $-3,107,187 |
| Other | ||||
| Ordinary Shares Number | $1,208,919 | $756,744 | $717,993 | $717,993 |
| Share Issued | $1,208,919 | $756,744 | $717,993 | $717,993 |
| Tangible Book Value | $1,919,420 | $3,144,448 | $4,675,596 | $1,423,393 |
| Invested Capital | $1,919,420 | $3,144,448 | $4,950,596 | $1,498,393 |
| Working Capital | $1,862,835 | $3,043,925 | $4,621,033 | $1,467,464 |
| Capital Lease Obligations | $47,605 | $136,594 | $154,520 | $207,961 |
| Total Capitalization | $1,919,453 | $3,144,448 | $4,675,596 | $1,473,552 |
| Additional Paid In Capital | $17,259,406 | $13,468,216 | $10,379,900 | $4,530,193 |
| Capital Stock | $154 | $75 | $574 | $546 |
| Common Stock | $121 | $75 | $574 | $387 |
| Preferred Stock | $33 | $0 | $0 | $159 |
| Long Term Capital Lease Obligation | $0 | $47,371 | $96,258 | $168,363 |
| Current Capital Lease Obligation | $47,605 | $89,223 | $58,262 | $39,598 |
| Current Accrued Expenses | $318,621 | $106,066 | $460,637 | $229,127 |
| Net PPE | $56,618 | $147,894 | $150,821 | $204,800 |
| Accumulated Depreciation | $-130,430 | $-127,544 | $-125,859 | - |
| Gross PPE | $187,048 | $275,438 | $276,680 | $204,800 |
| Other Properties | $46,754 | $135,144 | $150,821 | $204,800 |
| Machinery Furniture Equipment | $140,294 | $140,294 | $125,859 | - |
| Other Short Term Investments | - | - | $0 | $300,546 |
| Line Of Credit | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,950,747 | $-3,164,606 | $-1,831,161 | $-989,271 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,950,747 | $-3,150,172 | $-1,831,161 | $-989,271 |
| Cash Flow From Continuing Operating Activities | $-3,950,747 | $-3,150,172 | $-1,831,161 | $-989,271 |
| Operating Gains Losses | - | - | $747,396 | $-57,040 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-14,434 | $300,546 | $-300,546 |
| Cash Flow From Continuing Investing Activities | $0 | $-14,434 | $300,546 | $-300,546 |
| Capital Expenditure | - | $-14,434 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,841,872 | $1,611,601 | $4,963,530 | $2,096,909 |
| Financing Cash Flow | $2,841,872 | $1,336,601 | $5,238,530 | $2,096,909 |
| Cash Flow From Continuing Financing Activities | $2,841,872 | $1,336,601 | $5,238,530 | $2,096,909 |
| Net Preferred Stock Issuance | $2,841,872 | $1,611,601 | - | - |
| Preferred Stock Issuance | $2,841,872 | $1,611,601 | - | - |
| Net Common Stock Issuance | - | $0 | $4,963,530 | $2,096,909 |
| Common Stock Issuance | - | $0 | $4,963,530 | $2,096,909 |
| Other | ||||
| Repayment Of Debt | $0 | $-275,000 | $0 | - |
| Interest Paid Supplemental Data | $11,908 | $11,358 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $2,184,863 | $3,293,738 | $5,121,743 | $1,413,828 |
| Beginning Cash Position | $3,293,738 | $5,121,743 | $1,413,828 | $606,736 |
| Changes In Cash | $-1,108,875 | $-1,828,005 | $3,707,915 | $807,092 |
| Net Issuance Payments Of Debt | $0 | $-275,000 | $275,000 | $0 |
| Net Short Term Debt Issuance | $0 | $-275,000 | $0 | $0 |
| Short Term Debt Payments | $0 | $-275,000 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-14,434 | $0 | - |
| Purchase Of PPE | $0 | $-14,434 | $0 | - |
| Change In Working Capital | $113,235 | $-9,108 | $9,523 | $197,609 |
| Change In Other Working Capital | $-52,427 | $81,369 | $-113,655 | $69,035 |
| Change In Other Current Assets | $-599 | $-2,249 | $538 | $1,883 |
| Change In Payables And Accrued Expense | $410,681 | $-548,862 | $592,815 | $196,751 |
| Change In Accrued Expense | $160,506 | $-302,521 | $255,359 | $174,391 |
| Change In Payable | $250,175 | $-246,341 | $337,456 | $22,360 |
| Change In Account Payable | $250,175 | $-246,341 | $337,456 | $22,360 |
| Change In Prepaid Assets | $-244,420 | $460,634 | $-470,175 | $-70,060 |
| Other Non Cash Items | $200,000 | $121,200 | $9,612 | $6,834 |
| Stock Based Compensation | $749,396 | $1,355,016 | $747,396 | $728,799 |
| Depreciation Amortization Depletion | $2,886 | $1,685 | $0 | - |
| Depreciation And Amortization | $2,886 | $1,685 | $0 | - |
| Depreciation | $2,886 | $1,685 | - | - |
| Net Income From Continuing Operations | $-5,016,264 | $-4,618,965 | $-2,597,692 | $-1,865,473 |
| Issuance Of Debt | - | $0 | $275,000 | $0 |
| Proceeds From Stock Option Exercised | - | $1,611,601 | $0 | - |
| Net Long Term Debt Issuance | - | $-250,000 | $275,000 | $0 |
| Long Term Debt Payments | - | $-250,000 | $0 | - |
| Long Term Debt Issuance | - | $0 | $275,000 | $0 |
| Net Investment Purchase And Sale | - | $0 | $300,546 | $-300,546 |
| Sale Of Investment | - | $0 | $300,546 | - |
| Change In Other Current Liabilities | - | - | $17,671 | $22,870 |
| Change In Receivables | - | - | $-113,655 | $69,035 |
| Gain Loss On Investment Securities | - | - | $747,396 | $728,799 |
| Short Term Debt Issuance | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $-300,546 |
Fetched: 2026-02-02